Health Care/Hospital
I-Mab to Participate at the Piper Sandler Healthcare Conference
The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024 ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB, the "Company"), a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treat...
2024-11-21 20:00
686
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024
SHANGHAI, Nov. 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will part...
2024-11-21 18:00
650
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation
NANJING, China, Nov. 21, 2024 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company developing innovative therapies against cancer treatment resistance and metastasis, announced that China National Medical Products Administration (NMPA) has granted Ifebemtinib (IN10018) Breakthr...
2024-11-21 15:09
1108
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation
This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on their respective strengths. The overall optimization of the ADC drug has been achieved in a relatively short time. BEIJING, Nov. 20, 2024 /PRNewswi...
2024-11-21 13:01
784
United Imaging Installs Another Flagship uMR OMEGA®, in New Mexico
X-Ray Associates of New Mexico (XRANM), with their motto "We Don't Follow. We Lead.", took decisive action to have the 75 cm 3T MRI scanner installed and clinically operational within ten months of seeing images at RSNA 2023. HOUSTON, Nov. 20, 2024 /PRNewswire/ -- United Imaging, a global leader ...
2024-11-21 09:09
657
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
VANCOUVER, BC, Nov. 20, 2024 /PRNewswire/ -- Complete Genomics, a San Jose, Calif.-based genomic sequencer manufacturer, today announced at the 2024 Association for Molecular Pathology (AMP) Annual Meeting & Expo the launch of its mpox (MPXV) virus amplicon sequencing panel, part of its sequencin...
2024-11-21 01:01
659
NAYO Captivates Audiences at Analytica China 2024 with its Unique Exhibition Style
SHANGHAI, Nov. 20, 2024 /PRNewswire/ -- NAYO proudly participated in the 12th Analytica China & Labtech China Congress 2024, the international trade fair for laboratory technology, analysis and biotechnology inChina. Breaking away from traditional exhibition norms, NAYO demonstrated its cutting-e...
2024-11-20 22:30
1138
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity
The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preservingweight loss in Obesity LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech compan...
2024-11-20 22:00
1220
CABIO Deepens Commitment to Global Markets, Aiming to Serve International Clients and Pursue Long-Term International Partnerships
FRANKFURT, Germany, Nov. 20, 2024 /PRNewswire/ -- CABIO, a high-tech enterprise underpinned by biotechnology and listed on the Science and Technology Innovation Board (stock code: 688089), unveiled its innovative product, NeoHMOs®, at the Food Ingredients Europe event held inFrankfurt, Germany. ...
2024-11-20 21:00
633
2024 Global Healthy Longevity Conference Successfully Held
SHENZHEN, China, Nov. 20, 2024 /PRNewswire/ -- The 2024 Global Healthy Longevity Conference took place successfully in Shenzhen from 15-17 November. Under the theme "The Healthy Longevity Era: Technology-driven Anti-Aging," the conference combined exhibitions and forum presentations to explore ke...
2024-11-20 19:13
806
Head：China makes collaborative efforts in healing people with mental disorders with AI
BEIJING, Nov. 20, 2024 /PRNewswire/ -- After a long day at work, Ni Beiyue sits in front of his computer at home, eagerly immersing himself in the world of creating short videos with AI (artificial intelligence) tools. For nearly three hours, he brainstorms video content, generates mental images ...
2024-11-20 15:13
786
Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- On November 13th, a high-level delegation from the Alfasigma Group, led by Mr. Andriy Samoylovych, Chief Commercial Officer of Global Growth Markets, and Ms.Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou...
2024-11-20 10:38
1021
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...
2024-11-20 07:20
1111
Datasea Pre-Announces Full-Year Fiscal 2025 Revenue of $90 Million, Representing a Year-Over-Year Increase of 275%, with Expected Significant Gross Profit Improvement
BEIJING, Nov. 19, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustic high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the fiscal year ending Jun...
2024-11-19 22:45
1524
Xiao-I Corporation Announces Strategic Cooperation with Deafopia to Expand Market Outreach for AI Hardware Business
SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI), a leading artificial intelligence company ("Xiao-I") , today announced a strategic cooperation with Deafopia, a nonprofit organization dedicated to supporting businesses within the deaf and hard-of-hearing communities. Thi...
2024-11-19 22:45
1547
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS
NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...
2024-11-19 21:26
981
Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity
* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...
2024-11-19 21:00
1030
Hankyung.com introduces: Unmissable BFCM Deal on Amazon: Get EXTREME DUAL ARGININE PLUS, Free Shipping, and Subscribe & Save Options!
https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.jpg
2024-11-19 21:00
1013
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...
2024-11-19 20:30
807
RiDYMO® Platform Drives New Breakthroughs in highly potent PLK1 Inhibitors Development
BEIJING, Nov. 19, 2024 /PRNewswire/ -- With the support of the RiDYMO® platform, we are able to comprehensively explore various potential targets in drug development, including protein-protein interactions, kinases, GPCRs, ion channels, and transcription factors. Polo-like kinase 1 (PLK1) is a h...
2024-11-19 16:00
874
Week's Top Stories
Most Reposted
Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 305 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 299 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
[Picked up by 296 media titles]
2024-11-15 15:25
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 283 media titles]
2024-11-20 09:00
Most Read
Oxygen, HubSpot's leading solutions partner in Hong Kong & Greater China Expands to UAE
2024-11-15 15:25
8676
How "small apples" march into "big industry" in Yan'an
2024-11-15 17:39
5434
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
4839